selonsertib (GS-4997) / Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
selonsertib (GS-4997) / Gilead
STELLAR 4, NCT03053063 / 2016-004148-13: Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Checkmark Data from P3 STELLAR 4 trial in NASH
Feb 2019 - Feb 2019: Data from P3 STELLAR 4 trial in NASH
Checkmark Enrollment completion for P3 STELLAR 4 study
Apr 2018 - Apr 2018: Enrollment completion for P3 STELLAR 4 study
Terminated
3
883
Europe, Canada, Japan, US, RoW
SEL, selonsertib, GS-4997, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Gilead Sciences
Nonalcoholic Steatohepatitis
05/19
05/19
STELLAR 3, NCT03053050 / 2016-004374-18: Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

Checkmark Data from STELLAR 3 trial in NASH
Apr 2019 - Apr 2019: Data from STELLAR 3 trial in NASH
Checkmark Enrollment completion for P3 STELLAR 3 study
Apr 2018 - Apr 2018: Enrollment completion for P3 STELLAR 3 study
Terminated
3
808
Europe, Canada, Japan, US, RoW
SEL, selonsertib, GS-4997, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
Gilead Sciences
Nonalcoholic Steatohepatitis
06/19
06/19

Download Options